AVTAL FÖR SAMARBETE MED PATIENTORGANISATION
Avtalsnummer 2024087
AVTAL FÖR SAMARBETE MED PATIENTORGANISATION
Detta avtal (”Avtalet”) har ingåtts mellan Roche AB, xxx.xx. 556038-3100, Box 1228, 171 23 Solna, Sverige (”Roche”) och Insamlingsstiftelsen för Muskeldystrofiforskning (SMDF), xxx.xx. 822003 – 3552, c/o Xxxxx Xxxxx, Xxxxxxxxxxxxxxxx 00, 000 00 Xxxxxxxx Xxxxx (”Mottagaren”).
Bakgrund
Roche, Italfarmaco, patientföreningen för Duchennes och Beckers Muskeldystrofi (DBMD) samt SMDF skall i samverkan för att främja medvetenhet om sjukdomarna Xxxxxxx och Duchennes Muskeldystrofi, samt belysa de förhållanden som de drabbade lever under. Det ska ske under 2024, företrädesvis under Duchenne Awareness Day, som infaller den 7 september men inte begränsat till denna dag.
Parterna har mot ovanstående bakgrund därför enats om följande.
1 Samarbete - aktivitet
En extern leverantör skall utarbeta ett underlag samt presentera detta för media, med målsättningen att generera ett TV- eller radioinslag alternativt en nyhetsartikel eller intervju. En intervjuartikel skall framställas, vilken tillsammans med filmklipp syftar till att öka medvetenheten om sjukdomen Xxxxxxxxx och Xxxxxxx Muskeldystrofi. Detta material skall göras tillgängligt i såväl traditionella som sociala medier, samt i parternas respektive kanaler. Aktiviteten skall även följas upp och utvärderas. Materialet som produceras ska tillhöra DBMD och SMDF men aktiviteten utgör en gemensam och avgränsad insats.
(se bilaga).
2 Parternas åtaganden
2.1 Roche AB ansvarar för att bidra med finansiering av den externa leverantören. Roche AB är tillsammans med företaget Italfarmaco, DBMD och SMDF samarbetspartner till denna aktivitet. Dessutom ska Roche aktivt använda och sprida de artiklar och inslag som producerats i egna kanaler.
2.2 DBMD och SMDF åläggs ansvaret att bidra till produktionen av det erforderliga materialet samt medverka i de intervjuer och liknande åtaganden som kan komma att bli aktuella. Vidare skall DBMD och SMDF aktivt använda och sprida de artiklar och inslag som framställs.
2.3 I övrigt gäller LIF:s etiska regler för samarbete mellan LIF:s medlemsföretag och intresseföreningar/patientorganisationer enligt Läkemedelsbranschens etiska regelverk.
2.4 Parterna planerar mötet tillsammans och efter genomförd aktivitet ska parterna gemensamt utvärdera samarbetet.
Roche AB Postadress: Box 1228
171 23 Solna Sweden
Besöksadress: Xxxxx Xxxxxx allé 7 Ph: 00 000 00 00
Fax: 00 000 00 00
Bankgiro: 170-1457
Xxx.xx. 556038-3100 XXX.xx. SE556038310001
HCCO v5 171025
2
3 Ekonomi
3.1 Roche AB har åtagit sig att stå för hälften av kostnaderna för den externa leverantören.
3.2 Mottagaren har förbundit sig att täcka de utgifter som uppkommer till följd av medlemmarnas engagemang i projektet.
4 Öppenhet
4.1 Parterna är ense om att innehållet i denna överenskommelse får förmedlas till tredje part som också ska äga rätt att ta del av överenskommelsen.
4.2 Parterna är ense om att en kortversion av denna överenskommelse kommer att publiceras i LIFs samarbetsdatabas enligt Läkemedelsbranschens etiska regelverk.
5 Kontaktpersoner
5.1 Xxxxx AB har utsett Xxxxx Xxxxxxx, 070-2501204, xxxxx.xxxxxxx@xxxxx.xxx som kontaktperson i frågor som rör denna överenskommelse.
5.2 Föreningen har utsett Xxxxx Xxxxxxx, 073-5348553, xxxxx.xxxxxxx@xxxxxx.xxx, som kontaktperson i frågor som rör denna överenskommelse.
6 Behandling av personuppgifter
6.1 Roche samlar in följande kategorier av personuppgifter i förhållande till av mottagaren utsedd kontaktperson och eventuellt övriga personer hos mottagaren som är involverade i administrationen av aktiviteten: namn och kontaktuppgifter. Personuppgifterna kommer att behandlas av Roche med stöd av en intresseavvägning för att tillgodose Roches berättigade intresse av att administrera avtalsförhållandet med mottagaren. Mottagaren är skyldig att se till att kontaktpersonen och eventuella andra personer involverade, vars personuppgifter behandlas av Roche, fått information om Roches behandling av personuppgifter i enlighet med detta avtal.
6.2 Roche sparar de personuppgifter som Roche behandlar endast, som utgångspunkt, under avtalsförhållandet. Roche kan dock komma att spara personuppgifterna för den ytterligare tid som är nödvändig om Xxxxx är skyldigt enligt lag eller avtal att spara uppgifterna, eller för att Roche ska kunna fastställa, försvara eller göra gällande rättsliga anspråk. När personuppgifterna inte längre är nödvändiga för dessa ändamål kommer Xxxxx att på ett säkert sätt radera dem.
6.3 Då Roche ingår i en global koncern kommer Roche att överföra personuppgifter till koncernbolag för ovanstående ändamål. Överföringen till koncernbolagen stödjer sig på samma rättsliga grund som behandlingen i sig.
6.4 I förekommande fall är dessa koncernbolag etablerade i länder utanför EU/EES-området, som inte har samma skyddsnivå för personuppgifter som EU. För att säkerställa att personuppgifterna är skyddade ingår Roche, när så är nödvändigt, dataöverföringsavtal som inkluderar EU-kommissionens standardavtalsklausuler med mottagarna. En registrerad har rätt att på begäran få en kopia på klausulerna genom att kontakta Roche.
6.5 Roche AB är personuppgiftsansvarig för behandling av personuppgifter enligt detta avtal. Registrerade har rätt att begära rättelse av felaktiga eller ofullständiga personuppgifter som rör honom eller henne. Vidare har en registrerad rätt att begära att få information om Xxxxx behandlar några personuppgifter om honom eller henne och, om så är fallet, tillgång till de
personuppgifter som rör honom eller henne. Vid klagomål på Xxxxxx behandling av personuppgifter har den registrerade rätt att vända sig till Datainspektionen.
6.6 Vid frågor om Xxxxxx behandling av personuppgifter enligt denna bestämmelse kan den registrerade kontakta Xxxxx genom att skicka ett e-postmeddelande till Roches
dataskyddsombud på xxxxxxxxx.xxx@xxxxx.xxx, alternativt ett brev till Xxxxxx postadress som anges i ingressen till detta avtal.
7 Tidsperiod
7.1 Denna överenskommelse gäller från den dagen alla parter har skrivit under till 2024-12-30
7.2 Om någon av parterna väsentligen åsidosätter sina skyldigheter enligt denna överenskommelse och inte vidtar rättelse inom rimlig tid från det att parten anmodats skriftligen, har den andre parten rätt att med omedelbar verkan häva denna överenskommelse.
8 Tvist
8.1 Tvist i anledning av detta Avtal skall slutligt avgöras genom skiljedom enligt Xxxxxx för Förenklat Skiljeförfarande för Stockholms Handelskammares skiljedomsinstitut. Skiljeförfarandets säte ska vara Stockholm. Språket för förfarandet ska vara svenska. Svensk lag ska tillämpas på tvisten.
Roche AB Postadress: Box 1228
171 23 Solna Sweden
Besöksadress: Xxxxx Xxxxxx allé 7 Ph: 00 000 00 00
Fax: 00 000 00 00
Bankgiro: 170-1457
Xxx.xx. 556038-3100 XXX.xx. SE556038310001
HCCO v5 171025
4
9 Sista datum för underskrivet avtal i retur till Roche
9.1 Underskrivet avtal ska vara Roche tillhanda senast den 6/9 2024. Xxxxx förbehåller sig rätten att ställa in Aktiviteten om underskrivet avtal inte är Roche tillhanda senast angivet datum. Eventuell ersättning kommer då helt att utebli.
Denna överenskommelse har upprättats i två likalydande exemplar varav parterna erhållit varsitt.
06 september 2024
SMDF, datum
Roche AB, datum 06 September 2024
Xxxxx Xxxxx Ordförande
Xxxxx Xxxxxxx
Policy och Patient partner
06 September 2024
Roche AB, datum
Xxxxx Xxxxxxx
Leader, Healthcare Partnering
2024-08-20
To
Xxxxx Xxxxxxx Xxxxx
From
Xxxxxxx Xxxxxxx Reform Society
PROPOSAL
PR-SERVICES TO PUT THE SPOTLIGHT ON WORLD DUCHENNE AWARENESS DAY
Background
As part of Roche’s ongoing efforts to strengthen its working relationship with the patient organizations DBMD, Patientföreningen för Duchennes och Beckers muskeldystrofi and SMDF, Stiftelsen för muskeldystrofiforskning, Reform Society will assist with a PR-effort timed to coincide with, or happen in close proximity to, the World Duchenne Awareness Day, which happens on September 7, 2024.
Assignment
Reform Society offers the following services to Roche for World Duchenne Day (WDD):
1. Drafting a media brief, coaching the PAG-representative, contacting and attempting to sell it as either a TV/radio news segment or a news article/interview to several different news outlets, aiming for at least one news outlet to run the story/segment. Priority will be given to making it a morning news segment in the form of a studio interview (morgonsoffa).
2. Production (by Reform Society) of a written interview article, featuring a video clip, with a parent of chid with Xxxxxxxxx who tells the story of what it is like to receive this diagnosis, coping with the illness and hopes for the future. This article is intended to be made available for publication on the PAG website(s) and dissemination in PAG social media.
3. Follow-up meeting with the patient organizations to evaluate the activity and plan next steps and possible additional activities/areas of cooperation going forward.
Fee
Xxxxx Xxxxxxx 00 · 000 00 Xxxxxxxxx
Org nr 556866–8973 · pg 61 60 27-9 · bg 5238–8493
For the proposed activities, Reform Society will charge 86 000 SEK:
Step 1 (see above) | 40 000 SEK |
Step 2 (see above) | 40 000 SEK |
Step 3 (see above) | 6 000 SEK |
TOTAL | 86 000 SEK |
This is a joint project with Italfarmaco, where both companies support the PAG-organizations by tasking Reform Society with carrying out the above assignments, which have been outlined in cooperation with the PAG-organisations.
Proposal
All proposals are valid for 30 days from the date of signature.
Confirmation of assignments
The assignment is approved by the client by signing the proposal or the Agreement or using Reform Society's services according to the assignment description or the Agreement.
Execution of the assignment
Reform Society undertakes to carry out the assignment within agreed time and cost limits; but reserves itself for deviations from the pre-conditions of the assignment, assignment changes and circumstances beyond Reform Society's control. Reform Society has the right to use subcontractors; but must inform the client of this.
Reform Society has the right to terminate the Agreement with immediate effect if the client suspends payments, enters into liquidation or becomes bankrupt or insolvent.
Policies for charges
Reform Society shall charge the client a fee in accordance with the Agreement on a fixed price for a certain project or for time spent in accordance with applicable hourly rates. Unless otherwise agreed, Reform Society charges fee per hour spent.
If the actual time spent deviates significantly from what was expected, Reform Society is entitled to negotiate additional charges.
If the client wants Reform Society to provide services that are not part of an agreed assignment, Reform Society has the right to charge extra according to the current hourly rate, unless a specific price has been agreed for such additional services.
Expenses
In order to cover office expenses directly attributable to the client’s projects, Reform Society charges a 5% surcharge on fees. This includes costs for telephones, courier services, printing, copying, article searches in Retriever, TT calendar checks, postage and travel within the greater Stockholm area, use of meeting rooms in connection with workshops, i.e. costs that are directly attributable to the project’s implementation.
The surcharge does not include travel expenses outside the greater Stockholm area or other expenses. Other expenses are charged at actual cost. Reform Society charges a 10% surcharge to cover capital costs and management of subcontractor invoices.
2
Invoicing procedures
Unless otherwise agreed in the Agreement with the client, the following invoicing procedures shall apply:
Projects with a total fee of less than SEK 80,000 will be invoiced after work has been completed. Projects with a total fee exceeding SEK 80,000 are invoiced with 50% at the start of the project and 50% after the completion of the project. Projects with a total fee exceeding SEK 200,000 are invoiced according to an agreed invoicing plan.
For ongoing assignments, Reform Society charges the client on the 15th of each month for work done during prior the month. Payment terms are due 20 days from date of invoice.
VAT (moms)
All proposals and prices from Reform Society are quoted excluding VAT (MOMS). Reform Society's operations are subject to VAT (MOMS). Reform Society holds an F-tax certificate.
Interest
In case of late payment from clients, Reform Society will send a reminder.
Interest is charged after the invoice maturity date with the reference rate of the Swedish Riksbank and an additional 8 percentage points per month, in accordance with article 6 of the Swedish Interest Act (SFS 1975:635).
Copyright
The client acquires the right of disposal for the documents and other materials produced by Reform Society when full settlement for the work has been paid.
The client is not entitled to assign or lease the right to such material without the written approval of Reform Society. Materials that Reform Society has designated as internal or confidential may not be distributed to third parties.
Reform Society is responsible for its subcontractors waiving the right of disposal to this extent. Any remuneration for this will be charged to the client.
In all other respects Reform Society is not responsible for any copyright or other intellectual property right conferred to our subcontractors.
It is incumbent on the client to settle any remuneration owing to such copyright or other intellectual property right directly with relevant subcontractor of Reform Society.
Reform Society retains the right to use the customer's logo and name on its website and in other promotional materials.
Non-Solicitation
The client will not directly or indirectly engage or participate in the solicitation or attempt to solicit or in any manner encourage consultants to work for it. Such an inquiry must go to the staff manager at Reform Society. In the event of hiring a consultant, the recruitment fee is equivalent to three full months' salary of that consultant.
Confidentiality
Reform Society treats the client’s trade secrets and other details of a company-specific nature with confidentiality. Reform Society do not speak to third parties about its work unless the client has given its permission.
Suspended work and postponement of work
If assignments are canceled or postponed at the client's initiative, full compensation will be paid to the Reform Society under the originally signed agreement. The client has the right to cancel or postpone the agreed assignments only if this is agreed in writing and only subject to the terms indicated at that time.
Liability
Reform Society is not liable for any damages if it have exercised normal prudence. Reform Society is not liable under any circumstances for indirect damages such as lost profits, loss of goodwill and similar damages. Any claims must be submitted in writing to Reform Society no later than four weeks after completion of the work.
3
Force majeure
Reform Society shall not be held liable or responsible to the client nor be deemed to have defaulted under or breached the Agreement for failure or delay in fulfilling or performing any obligation under the Agreement when such failure or delay is caused by or results from causes beyond our control. Such causes include acute illness, governmental action, new or amended legislation, labor market conflicts and thus equal circumstances.
Disputes
The Parties' rights and obligations under this Agreement shall be governed by the substantive law of Sweden without regards to its conflict of laws provisions. Any dispute, controversy or claim arising out of or in connection with this agreement, or the breach, termination or invalidity thereof, shall be finally settled by arbitration in accordance with the Rules for Expedited Arbitrations of the Arbitration Institute of the Stockholm Chamber of Commerce. The parties undertake to keep the arbitration procedure concerning this Agreement confidential. No matter what kind of information, documentation or other material relating to the arbitration process is disclosed during the arbitration process, the information may only be used in the arbitration process.
4
Certificate Of Completion
Envelope Id: 14466D8A2F194B679C6B55E94DF5D636 Status: Completed Subject: Complete with Docusign: SigneringSMDF
Source Envelope:
Document Pages: 8 Signatures: 3 Envelope Originator:
Certificate Pages: 4 Initials: 0 Xxxxxxx Xxxxxxxx
AutoNav: Enabled
EnvelopeId Stamping: Disabled
Time Zone: (UTC+01:00) Amsterdam, Berlin, Bern, Rome, Stockholm, Vienna
Xxxxxxxxxxxxxxxxx 000
Basel, Basel-Stadt 4070 xxxxxxx.xxxxxxxx@xxxxx.xxx IP Address: 158.174.115.188
Record Tracking
Status: Original
9/6/2024 9:12:19 AM
Holder: Xxxxxxx Xxxxxxxx
Location: DocuSign
Signer Events Signature Timestamp
Xxxxx Xxxxxxx xxxxx.xxxxxxx@xxxxx.xxx Nordic_408
Security Level: Email, Account Authentication
(None) Signature Adoption: Pre-selected Style
Using IP Address: 217.213.142.30
Sent: 9/6/2024 9:13:50 AM Viewed: 9/6/2024 9:29:13 AM Signed: 9/6/2024 9:29:43 AM
Electronic Record and Signature Disclosure:
Accepted: 9/3/2021 9:56:56 AM
ID: 5afb7b35-7a03-435b-892e-29d32c0197dd
Company Name: X. Xxxxxxxx-La Roche Ltd
Xxxxx Xxxxxxx xxxxx.xxxxxxx@xxxxx.xxx
Security Level: Email, Account Authentication (None)
Signature Adoption: Pre-selected Style Using IP Address: 196.3.50.247
Sent: 9/6/2024 9:29:45 AM Viewed: 9/6/2024 11:57:12 AM Signed: 9/6/2024 11:57:46 AM
Electronic Record and Signature Disclosure:
Accepted: 9/6/2024 11:57:12 AM
ID: 3bc06831-d233-45de-bd8a-f5de03ed07ac Company Name: X. Xxxxxxxx-La Roche Ltd
Xxxxx Xxxxx xxxxx.xxxxx@xxxxxx.xx
Security Level: Email, Account Authentication (None)
Signature Adoption: Drawn on Device Using IP Address: 176.10.136.37
Sent: 9/6/2024 11:57:48 AM Viewed: 9/6/2024 12:58:42 PM Signed: 9/6/2024 1:01:48 PM
Electronic Record and Signature Disclosure:
Accepted: 9/6/2024 12:58:42 PM
ID: 83a606e7-9c3b-4c98-9ce6-dfd0f64dde38 Company Name: X. Xxxxxxxx-La Roche Ltd
In Person Signer Events | Signature | Timestamp |
Editor Delivery Events | Status | Timestamp |
Agent Delivery Events | Status | Timestamp |
Intermediary Delivery Events | Status | Timestamp |
Certified Delivery Events | Status | Timestamp |
Carbon Copy Events | Status | Timestamp |
Witness Events | Signature | Timestamp |
Notary Events | Signature | Timestamp |
Envelope Summary Events | Status | Timestamps |
Envelope Sent | Hashed/Encrypted | 9/6/2024 9:13:50 AM |
Certified Delivered | Security Checked | 9/6/2024 12:58:42 PM |
Signing Complete | Security Checked | 9/6/2024 1:01:48 PM |
Completed | Security Checked | 9/6/2024 1:01:48 PM |
Payment Events | Status | Timestamps |
Electronic Record and Signature Disclosure | ||
Electronic Record and Signature Disclosure created on: 1/3/2019 2:16:57 PM Parties agreed to: Xxxxx Xxxxxxx, Xxxxx Xxxxxxx, Xxxxx Xxxxx
Guidelines for the use of the DocuSign electronic signing system within X. Xxxxxxxx-La Roche and companies of the Roche Group
LEGAL DISCLOSURE
By placing my electronic signature on this document, I expressly consent to use and rely on Electronic and Digital Signatures and I understand my signature will have the same binding effect as if I was providing a handwritten signature.
I also confirm the email address that I am using as a valid one to be notified and identified electronically, for example through the DocuSign System, and/or to identify me as the signer of the document. I should inform Roche in the case that the email address changes.
CONSUMER DISCLOSURE
From time to time, X. Xxxxxxxx-La Roche and companies of the Roche Group (hereinafter referred to as we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign, Inc. (DocuSign) electronic signing system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to these terms and conditions, please confirm your consent by clicking the 'I agree' button at the bottom of this document.
Consequences of changing your mind
To indicate to us that you are changing your mind, you must withdraw your consent using the DocuSign 'Withdraw Consent' form on the signing page of a DocuSign envelope instead of signing it. This will indicate to us that you have withdrawn your consent to receive required notices and disclosures electronically from us and you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.
All notices and disclosures will be sent to you electronically
Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.
How to contact us
You may contact us to let us know of your changes as to how we may contact you electronically, to request certain information from us and to withdraw your prior consent to receive notices and disclosures electronically. To do so contact the sender of the envelope.
To advise us of your new email address
To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to the sender of the envelope and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address. In addition, you must notify DocuSign, Inc. to arrange for your new email address to be reflected in your DocuSign account by following the process for changing email in the DocuSign system.
To withdraw your consent
To inform us that you no longer want to receive future notices and disclosures in electronic format you may decline to sign a document from within your DocuSign session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent.
Acknowledging your access and consent to receive materials electronically
To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please verify that you were able to read this electronic disclosure and that you also were able to print on paper or electronically save this page for your future reference and access or that you were able to email this disclosure and consent to an address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format on the terms and conditions described above, please let us know by clicking the 'I agree' button below.
By checking the 'I agree' box, I confirm that:
● I can access and read this Electronic CONSENT TO ELECTRONIC RECEIPT OF ELECTRONIC CONSUMER DISCLOSURES document; and
● I can print on paper the disclosure or save or send the disclosure to a place where I can print it, for future reference and access; and
● Until or unless I notify the account owner as described above, I consent to receive from exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to me by the account owner during the course of my relationship with you.
● I acknowledge the information included in the† DocuSign Privacy Policy